SG11201609993YA - Treatment of immune disorders - Google Patents

Treatment of immune disorders

Info

Publication number
SG11201609993YA
SG11201609993YA SG11201609993YA SG11201609993YA SG11201609993YA SG 11201609993Y A SG11201609993Y A SG 11201609993YA SG 11201609993Y A SG11201609993Y A SG 11201609993YA SG 11201609993Y A SG11201609993Y A SG 11201609993YA SG 11201609993Y A SG11201609993Y A SG 11201609993YA
Authority
SG
Singapore
Prior art keywords
treatment
immune disorders
immune
disorders
Prior art date
Application number
SG11201609993YA
Other languages
English (en)
Inventor
Silviu Itescu
Paul Simmons
Original Assignee
Mesoblast Internat Sàrl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902194A external-priority patent/AU2014902194A0/en
Application filed by Mesoblast Internat Sàrl filed Critical Mesoblast Internat Sàrl
Publication of SG11201609993YA publication Critical patent/SG11201609993YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
SG11201609993YA 2014-06-10 2015-06-01 Treatment of immune disorders SG11201609993YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014902194A AU2014902194A0 (en) 2014-06-10 Treatment of immune disorders
AU2014902257A AU2014902257A0 (en) 2014-06-13 Treatment of immune disorders 2
PCT/EP2015/062138 WO2015189063A1 (en) 2014-06-10 2015-06-01 Treatment of immune disorders

Publications (1)

Publication Number Publication Date
SG11201609993YA true SG11201609993YA (en) 2016-12-29

Family

ID=53385603

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609993YA SG11201609993YA (en) 2014-06-10 2015-06-01 Treatment of immune disorders

Country Status (9)

Country Link
US (4) US10624930B2 (cg-RX-API-DMAC7.html)
EP (2) EP3154565B1 (cg-RX-API-DMAC7.html)
JP (5) JP6800757B2 (cg-RX-API-DMAC7.html)
KR (4) KR20170007854A (cg-RX-API-DMAC7.html)
CN (2) CN114129598A (cg-RX-API-DMAC7.html)
AU (2) AU2015273799B2 (cg-RX-API-DMAC7.html)
CA (1) CA2950804C (cg-RX-API-DMAC7.html)
SG (1) SG11201609993YA (cg-RX-API-DMAC7.html)
WO (1) WO2015189063A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
CA2837895C (en) * 2011-06-03 2021-07-27 Mesoblast, Inc. Methods of treating or preventing neurological diseases
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CN104136034B (zh) 2011-11-30 2018-04-24 安斯泰来再生医药协会 间充质基质细胞及其相关用途
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
SG11201609993YA (en) * 2014-06-10 2016-12-29 Mesoblast Internat Sàrl Treatment of immune disorders
JP7249951B2 (ja) * 2017-03-31 2023-03-31 ウィスコンシン アラムニ リサーチ ファンデーション 標的臓器の細胞外構成成分を使用する治療用細胞の作製
CN106929474B (zh) * 2017-03-31 2021-09-14 北京恒峰铭成生物科技有限公司 一种m2巨噬细胞诱导剂
WO2019108756A1 (en) 2017-11-29 2019-06-06 Figene, Llc Interaction of fibroblasts and immune cells for activation and uses thereof
CN112007165B (zh) * 2020-08-27 2021-10-08 北京大学人民医院 巨噬细胞极化调节剂及其在促进血小板生成中的应用
JP2025540288A (ja) * 2022-12-09 2025-12-11 メゾブラスト・インターナショナル・エスアーエールエル 細胞組成物を用いた炎症治療方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US20050239897A1 (en) * 2004-03-22 2005-10-27 Pittenger Mark F Mesenchymal stem cells and uses therefor
AU2005287855B2 (en) * 2004-09-24 2011-06-16 Mesoblast, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
WO2006108229A1 (en) 2005-04-12 2006-10-19 Angioblast Systems, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
CN102076844B (zh) * 2008-06-30 2013-08-07 成血管细胞系统公司 采用组合疗法的眼病和过度血管新生的治疗
NZ592726A (en) * 2008-11-19 2012-12-21 Anthrogenesis Corp Amnion derived adherent cells
JP5678360B2 (ja) * 2009-09-28 2015-03-04 株式会社ジーシー 間葉系幹細胞の培養方法
US20140017787A1 (en) * 2010-10-11 2014-01-16 Aline M. Betancourt Mesenchymal stem cells and related therapies
CN104136034B (zh) * 2011-11-30 2018-04-24 安斯泰来再生医药协会 间充质基质细胞及其相关用途
CN102899293A (zh) 2012-11-01 2013-01-30 上海市肺科医院 促血管生成素1基因修饰的间充质干细胞、及其构建方法与应用
AU2015243575B2 (en) * 2014-04-07 2017-11-02 Mesoblast International Sarl Improved stem cell composition
SG11201609993YA (en) 2014-06-10 2016-12-29 Mesoblast Internat Sàrl Treatment of immune disorders

Also Published As

Publication number Publication date
WO2015189063A1 (en) 2015-12-17
US10624930B2 (en) 2020-04-21
CN114129598A (zh) 2022-03-04
CN106659743A (zh) 2017-05-10
KR20250143870A (ko) 2025-10-02
AU2020244403A1 (en) 2020-10-29
EP3154565B1 (en) 2023-05-03
EP4137146A1 (en) 2023-02-22
US20230141347A1 (en) 2023-05-11
JP2025109787A (ja) 2025-07-25
AU2020244403B2 (en) 2024-03-07
EP3154565A1 (en) 2017-04-19
JP2023090901A (ja) 2023-06-29
CA2950804C (en) 2023-08-22
KR20230038590A (ko) 2023-03-20
JP2017526619A (ja) 2017-09-14
US20200281984A1 (en) 2020-09-10
HK1231386A1 (en) 2017-12-22
CN106659743B (zh) 2022-03-01
KR20170007854A (ko) 2017-01-20
AU2015273799B2 (en) 2020-07-02
JP2021028337A (ja) 2021-02-25
JP7009594B2 (ja) 2022-02-10
US20250319134A1 (en) 2025-10-16
KR20240135079A (ko) 2024-09-10
CA2950804A1 (en) 2015-12-17
JP7680493B2 (ja) 2025-05-20
JP7279212B2 (ja) 2023-05-22
KR102865313B1 (ko) 2025-09-29
JP6800757B2 (ja) 2020-12-16
KR102704978B1 (ko) 2024-09-09
AU2015273799A1 (en) 2016-12-15
US11406669B2 (en) 2022-08-09
US12257270B2 (en) 2025-03-25
JP2022040254A (ja) 2022-03-10
US20170106023A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL252839A0 (en) Treatment of boils
GB201701673D0 (en) Methods of well treatment
PL3851537T3 (pl) Leczenie hiperbilirubinemii
IL285003A (en) Treatment of episode disorders
SG11201609652RA (en) Treatment of polybacterials infections
SG11201609993YA (en) Treatment of immune disorders
GB201410116D0 (en) Method of treatment
GB201412578D0 (en) Treatment of neurological diseases
GB201416832D0 (en) Methods of treatment
IL253028B (en) treatment method
GB201408387D0 (en) Treatment of respiratory disorders
SG11201702700UA (en) Methods for the treatment of peri-implantitis
GB201408297D0 (en) Treatment of cancer
GB201607388D0 (en) Treatment of impulsivity-related disorders
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201411027D0 (en) Treatment
GB201512139D0 (en) Methods of treatment
GB201417456D0 (en) Treatment of cancer
GB201412411D0 (en) Treatment
GB201407806D0 (en) Treatment of fibrosis
AU2014902194A0 (en) Treatment of immune disorders
AU2014902257A0 (en) Treatment of immune disorders 2
GB201602784D0 (en) New treatment of CFTR-related disorders
GB201414023D0 (en) Treatment of autoimmune diseases